DRG Market Assessment reports

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum, characterized by diarrhea, abdominal pain, rectal bleeding, fever, and weight loss. The…

Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…

This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and…

Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases)…

Numerous antidepressant therapies are available to treat major depressive disorder (MDD), many of which have long been generic and are entrenched in medical practice. However, most current…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just in the past year…

Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment in China has been…